ROG
Roche Holding AG
Is ROG Halal?
Pharmaceutical and diagnostics business is generally permissible, but debt/assets is just above common limits.
What You Should Know
Roche's 2025 finance report shows CHF 101,801 million of assets, CHF 34,654 million of debt and CHF 61,516 million of sales; Q1 2026 sales were CHF 14.7 billion. Medicines and diagnostics are broadly life-preserving, but ingredients, research, licensing and clinical ethics remain qualitative questions.
⚠️ Concerns
- •Debt/assets is 34.04%, above common 33.33% limits
- •Animal-derived materials and clinical research require review
- •Product, licensing and end-use exposure is not fully allocated
Current quantitative Sharia screen
Based on 2025 finance report figures for the period ended 2025-12-31; calculated 2026-07-14.
34,654 / 101,801
17,317 / 101,801
18,272 / 101,801
- Financial
- Fails
- Overall
- Fails
Debt/assets is 34.04%, above the examined 33.333% limit; liquidity/assets is 16.87% and receivables plus cash/assets is 17.94%, while income and activity classification remain incomplete.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 34.04%, above the examined MSCI total-assets limit; the debt failure is independent of the incomplete business classification.
- Financial
- Fails
- Overall
- Fails
Debt/assets is above the examined Malaysia limit; this is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Fails
Historical market-cap inputs are not stored and the income numerator is unavailable; the debt failure remains material.
Business-activity disclosure
Roche's pharmaceutical and diagnostics businesses are generally life-preserving and permissible in broad qualitative terms, but product ingredients, research, licensing and end-use questions remain product-specific.
Limitation: The public report does not provide a universal prohibited-revenue allocation or a school-neutral treatment of animal-derived materials and clinical research.
Purification
No comparable conventional-interest numerator is separately disclosed; no purification percentage is inferred.
Inputs, assumptions and primary sources
- Amounts are CHF millions from the 2025 finance report.
- Debt is long-term CHF 30,722 million plus short-term CHF 3,932 million; cash is CHF 6,975 million, marketable securities CHF 10,342 million and accounts receivable CHF 11,297 million.
- FY2025 sales are CHF 61,516 million; Q1 2026 sales of CHF 14.7 billion are supplementary freshness context, not mixed into the FY denominator.
- The filing does not isolate a methodology-neutral conventional-interest income or prohibited-product revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →